Antibody Drug Conjugates

Antibody–Drug Conjugates (ADCs) represent one of the most advanced platforms in targeted cancer therapy, integrating the high selectivity of monoclonal antibodies with the potent cytotoxic activity of small-molecule drugs. The research activity focuses on the chemical design and sustainable synthesis of high-value payloads and intermediates intended for ADC development, combining expertise in medicinal chemistry and catalysis. The scientific contributions of the group include the development of novel heterocyclic scaffolds with cytotoxic potential, supported by detailed structure–activity relationship studies, and the design of efficient synthetic pathways to access advanced intermediates suitable for bioconjugation. Particular attention is devoted to catalytic methodologies that enhance reaction efficiency, selectivity, and scalability while reducing waste and environmental impact. Research outcomes reported in publications highlight the construction of modular synthetic platforms for the preparation of ADC-relevant building blocks, as well as the optimization of functional groups compatible with conjugation strategies. This approach ensures chemical robustness, reproducibility, and alignment with sustainable pharmaceutical manufacturing principles. Through the integration of advanced organic synthesis and environmental responsibility, this research positions ADC development within a broader framework of sustainable medicinal chemistry, fostering innovation that bridges therapeutic efficacy and circular process design.